Article
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
American journal of hematology - 1 Jun 2020
Zhao Shuangtao, Kanagal-Shamanna Rashmi, Navsaria Lucy, Ok Chi Young, Zhang Shaojun, Nomie Krystle, Han Guangchun, Hao Dapeng, Hill Holly A, Jiang Changying, Yao Yixin, Nastoupil Loretta, Westin Jason, Fayad Luis, Nair Ranjit, Steiner Raphel, Ahmed Sairah, Samaniego Felipe, Iyer Swaminathan P, Oriabure Onyeka, Chen Wendy, Song Xingzhi, Zhang Jianhua, Badillo Maria, Moghrabi Omar, Aranda Jorge, Tang Guilin, Yin C Cameron, Patel Keyur, Medeiros Leonard Jeffrey, Li Shaoying, Vega Francisco, Thirumurthi Selvi, Xu Guofan, Neelapu Sattva, Flowers Christopher R, Romaguera Jorge, Fowler Nathan, Wang Linghua, Wang Michael L, Jain Preetesh
Abstract excerpt
Venetoclax is effective in relapsed patients with mantle cell lymphoma (MCL). Mechanisms of resistance to venetoclax in MCL are poorly understood. We describe the clinical outcomes and genomic characteristics of 24 multiply relapsed patients (median of five prior lines of therapy) who received venetoclax-based therapies; 67% had progressed on BTK inhibitors (BTKi) and 54% had blastoid or pleomorphic histology....
Topics
Join the communities discussing this publication.